Michael Justin S, Lee Bong-Seop, Zhang Miqin, Yu John S
Department of Neurosurgery, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Department of Materials Science and Engineering, University of Washington, Seattle, Washington, USA.
J Transl Int Med. 2018 Oct 9;6(3):128-133. doi: 10.2478/jtim-2018-0025. eCollection 2018 Sep.
Glioblastoma multiforme (GBM), a grade IV astrocytoma as defined by the World Health Organization (WHO) criteria, is the most common primary central nervous system tumor in adults. After treatment with the current standard of care consisting of surgical resection, concurrent temozolomide (TMZ), and radiation, the median survival is only 15 months. The limited and less-effective treatment options for these highly aggressive GBMs call for the development of new techniques and the improvement of existing technologies. Nanotechnology has shown promise in treating this disease, and some nanomaterials have demonstrated the ability to cross the blood-brain barrier (BBB) and remain in GBM tissues. Although the retention of nanoparticles (NPs) in GBM tissue is necessary to elicit an antitumor response, the delivery of the NP needs to be enhanced. Current research in nanotechnology is directed at increasing the active targeting of GBM tissue not only for the aid of chemotherapeutic drug delivery but also for imaging studies. This review is aimed at describing advancements in increasing nanotechnology specificity to GBM tissue.
多形性胶质母细胞瘤（GBM）是根据世界卫生组织（WHO）标准定义的IV级星形细胞瘤，是成人中最常见的原发性中枢神经系统肿瘤。采用包括手术切除、同步替莫唑胺（TMZ）和放疗在内的当前标准治疗方案后，中位生存期仅为15个月。对于这些高度侵袭性的GBM，治疗选择有限且效果不佳，因此需要开发新技术并改进现有技术。纳米技术在治疗这种疾病方面已显示出前景，一些纳米材料已证明能够穿过血脑屏障（BBB）并保留在GBM组织中。尽管纳米颗粒（NPs）保留在GBM组织中对于引发抗肿瘤反应是必要的，但NP的递送仍需增强。目前纳米技术的研究旨在提高GBM组织的主动靶向性，不仅用于辅助化疗药物递送，还用于成像研究。本综述旨在描述提高纳米技术对GBM组织特异性方面的进展。
